GAB1 – novel regulator of migration capacity and tonic AKT activity in CLL: Implications for combinatorial therapy with BCR inhibitors.

ŠEDA, Václav, Eva HOFERKOVÁ, Laura ONDRIŠOVÁ, Lenka KOŠŤÁLOVÁ, Sonali SHARMA, Tomáš LOJA, Daniel ZICHA, Jan VERNER, Šárka POSPÍŠILOVÁ, Yvona BRYCHTOVÁ, Anna PANOVSKÁ, Michael DOUBEK, Jiří MAYER and Marek MRÁZ. GAB1 – novel regulator of migration capacity and tonic AKT activity in CLL: Implications for combinatorial therapy with BCR inhibitors. In XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL). 2021.

Basic information

• Original name: GAB1 – novel regulator of migration capacity and tonic AKT activity in CLL: Implications for combinatorial therapy with BCR inhibitors.
• Authors: ŠEDA, Václav, Eva HOFERKOVÁ, Laura ONDRIŠOVÁ, Lenka KOŠŤÁLOVÁ, Sonali SHARMA, Tomáš LOJA, Daniel ZICHA, Jan VERNER, Šárka POSPÍŠILOVÁ, Yvona BRYCHTOVÁ, Anna PANOVSKÁ, Michael DOUBEK, Jiří MAYER and Marek MRÁZ.
• Edition: XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL), 2021.

Other information

• Type of outcome: Conference abstract
• Confidentiality degree: is not subject to a state or trade secret
• Organization unit: Central European Institute of Technology

Links

• MUNI/A/1595/2020, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VIII (Acronym: VýDiTeHeMa VIII)

Investor: Masaryk University

• NU20-03-00292, research and development project: Name: PRIORITIZACE KOMBINACÍ LÉČIV U CHRONICKÉ LYMFOCYTÁRNÍ LEUKÉMIE NA ZÁKLADĚ ANALÝZY ADAPTACE BUNĚK NA IBRUTINIB A IDELALISIB IN VIVO
• 802644, interní kód MU: Name: Signaling propensity in the microenvironment of B cell chronic lymphocytic leukemia (Acronym: LeukemiaEnviron)

Investor: European Union, ERC (Excellent Science)